Found: 30
Select item for more details and to access through your institution.
Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 3, p. 253, doi. 10.1007/s00280-023-04629-1
- By:
- Publication type:
- Article
Variations in the plasticity of functional traits indicate the differential impacts of abiotic and biotic factors on the structure and growth of trees in tropical dry forest fragments.
- Published in:
- Frontiers in Plant Science, 2024, p. 1, doi. 10.3389/fpls.2023.1181293
- By:
- Publication type:
- Article
Effect of Concurrent Use of Memantine on The Efficacy of Masupirdine (SUVN‐502): A Post‐hoc Analysis of a Phase‐2 Randomized Placebo‐Controlled Study.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.062688
- By:
- Publication type:
- Article
Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study.
- Published in:
- Neurology & Therapy, 2022, v. 11, n. 4, p. 1583, doi. 10.1007/s40120-022-00390-4
- By:
- Publication type:
- Article
Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 9, p. 747, doi. 10.1007/s40261-022-01189-9
- By:
- Publication type:
- Article
Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization.
- Published in:
- Psychopharmacology, 2022, v. 239, n. 7, p. 2215, doi. 10.1007/s00213-022-06108-6
- By:
- Publication type:
- Article
First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects.
- Published in:
- Clinical Drug Investigation, 2021, v. 41, n. 5, p. 469, doi. 10.1007/s40261-021-01027-4
- By:
- Publication type:
- Article
SUVN‐I6107: A novel muscarinic M1 receptor‐positive allosteric modulator (M1‐PAM) for the treatment of cognitive deficits: Biomarkers (non‐neuroimaging)/Prognostic utility.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.039288
- By:
- Publication type:
- Article
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.
- Published in:
- Clinical Drug Investigation, 2020, v. 40, n. 7, p. 603, doi. 10.1007/s40261-020-00920-8
- By:
- Publication type:
- Article
P4‐660: TRIPLE THERAPY WITH MASUPIRDINE (SUVN‐502), A 5‐HT<sub>6</sub> ANTAGONIST, DONEPEZIL AND MEMANTINE IN MODERATE ALZHEIMER'S DISEASE: BASELINE PATIENT CHARACTERISTICS IN A PHASE‐2A STUDY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P1584, doi. 10.1016/j.jalz.2019.09.026
- By:
- Publication type:
- Article
P2‐031: SAFETY, TOLERABILITY AND HUMAN PHARMACOKINETICS OF SUVN‐502, A POTENT AND PURE 5‐HT<sub>6</sub> RECEPTOR ANTAGONIST.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P583, doi. 10.1016/j.jalz.2019.06.1253
- By:
- Publication type:
- Article
P1‐075: IN‐VIVO CHARACTERIZATION OF SUVN‐I2004: AN M<sub>1</sub> POSITIVE ALLOSTERIC MODULATOR (PAM) IN ANIMAL MODELS OF COGNITION AND SAFETY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P299, doi. 10.1016/j.jalz.2018.06.077
- By:
- Publication type:
- Article
Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects.
- Published in:
- Clinical Drug Investigation, 2018, v. 38, n. 5, p. 401, doi. 10.1007/s40261-018-0618-4
- By:
- Publication type:
- Article
SUVN-G3031, A SELECTIVE H3 RECEPTOR INVERSE AGONIST: ASSESSMENT OF SAFETY, TOLERABILITY AND PHARMACOKINETICS IN HEALTHY HUMAN VOLUNTEERS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P261, doi. 10.1016/j.jalz.2017.06.130
- By:
- Publication type:
- Article
SUVN-D4010: A POTENT AND SELECTIVE 5-HT4 RECEPTOR PARTIAL AGONIST— ASSESSMENT OF SAFETY, TOLERABILITY AND PHARMACOKINETICS IN HEALTHY HUMAN VOLUNTEERS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P463, doi. 10.1016/j.jalz.2017.06.476
- By:
- Publication type:
- Article
SUVN-502 + DONEPEZIL + MEMANTINE (TRIPLE COMBINATION) REPRESENTS A PROMISING NEW APPROACH FOR SYMPTOMATIC TREATMENT OF ALZHEIMER’S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P617, doi. 10.1016/j.jalz.2017.06.681
- By:
- Publication type:
- Article
Evaluation of clinical chemistry analytes from a single mouse using diluted plasma: effective way to reduce the number of animals in toxicity studies.
- Published in:
- Laboratory Animals, 2016, v. 50, n. 5, p. 354, doi. 10.1177/0023677215620969
- By:
- Publication type:
- Article
SUVN-502, POTENT AND PURE 5-HT6 RECEPTOR ANTAGONIST: PROOF-OF-CONCEPT STUDY DESIGN IN MODERATE ALZHEIMER’S DISEASE PATIENTS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P434, doi. 10.1016/j.jalz.2016.06.833
- By:
- Publication type:
- Article
SUVN-G3031, A POTENT AND SELECTIVE H3 RECEPTOR INVERSE AGONIST: SAFETY, TOLERABILITY AND PHARMACOKINETICS IN HUMANS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P618, doi. 10.1016/j.jalz.2016.06.1230
- By:
- Publication type:
- Article
SUVN-D4010, A POTENT AND SELECTIVE 5-HT4 RECEPTOR PARTIAL AGONIST: SAFETY, TOLERABILITY AND PHARMACOKINETICS IN HUMANS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P823, doi. 10.1016/j.jalz.2016.06.1673
- By:
- Publication type:
- Article
SUVN-I4035 - PRECLINICAL CHARACTERIZATION OF NOVEL MUSCARINIC M1 POSITIVE ALLOSTERIC MODULATOR.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P870, doi. 10.1016/j.jalz.2016.06.1794
- By:
- Publication type:
- Article
Determining the effect of storage conditions on prothrombin time, activated partial thromboplastin time and fibrinogen concentration in rat plasma samples.
- Published in:
- Laboratory Animals, 2015, v. 49, n. 4, p. 311, doi. 10.1177/0023677215597137
- By:
- Publication type:
- Article
Suvn-g3031, an h3 receptor inverse agonist, produces procognitive effects without affecting sleep in preclinical models.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2015, v. 11, n. 7, p. P475, doi. 10.1016/j.jalz.2015.06.525
- By:
- Publication type:
- Article
Suvn-d4010: A novel 5-ht4 receptor partial agonist for the treatment of Alzheimer’s disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2015, v. 11, n. 7, p. P475, doi. 10.1016/j.jalz.2015.06.524
- By:
- Publication type:
- Article
Suvn-i1312004, a novel m1 muscarinic acetylcholine receptor-positive allosteric modulator: Potential for the treatment of Alzheimer’s disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2015, v. 11, n. 7, p. P615, doi. 10.1016/j.jalz.2015.06.859
- By:
- Publication type:
- Article
Safety, tolerability, and pharmacokinetics of a potent and selective 5-ht6 receptor antagonist, SUVN-502, following multiple ascending doses in healthy elderly subjects, and effect of gender and food on single-dose pharmacokinetics.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2015, v. 11, n. 7, p. P748, doi. 10.1016/j.jalz.2015.06.1669
- By:
- Publication type:
- Article
Splenic abscess: Plasmodium vivax with secondary Escherichia coli infection.
- Published in:
- 2015
- By:
- Publication type:
- Case Study
Effect of gender and food on the single-dose pharmacokinetics of SUVN-502, a potent and selective 5-HT6 receptor antagonist.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2014, v. 10, p. P772, doi. 10.1016/j.jalz.2014.05.1484
- By:
- Publication type:
- Article
Characteristics of spectral aerosol optical depths over India during ICARB.
- Published in:
- Journal of Earth System Science, 2008, v. 117, n. S1, p. 303, doi. 10.1007/s12040-008-0033-y
- By:
- Publication type:
- Article